Calvin Sandra — SEC insider filings
SEC reporting owner CIK 1882909. 20 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2022-01-26 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 30 legs across 20 filings — 205,097 shares, $6,297,191 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 45.
- Largest priced transaction: sale of 67,115 shares @ $36.00 ($2,416,140) in Travere Therapeutics, Inc., filed 2025-11-06.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | 20 | — | 30 legs · 205,097 sh · $6,297,191 | 45 |
Insider filings — Calvin Sandra
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 2,500 @ $27.50 · Option exercise (M): 1,250 @ $22.40 · Option exercise (M): 1,625 @ $20.46 · Sale (S): 4,275 @ $62.13 · Sale (S): 800 @ $62.85 · Sale (S): 300 @ $63.66 · +3 more | EDGAR |
| 2026-04-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 2,500 @ $22.40 · Option exercise (M): 6,250 @ $8.93 · Option exercise (M): 6,500 @ $20.46 · Sale (S): 21,977 @ $41.07 · Option exercise (M): 2,500 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 15,180 @ $0 · Sale (S): 4,333 @ $32.12 · Grant/award (A): 20,160 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 7,402 @ $40 | EDGAR |
| 2025-12-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,910 @ $36 | EDGAR |
| 2025-11-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $25.25 · Option exercise (M): 17,500 @ $26.88 · Option exercise (M): 15,000 @ $27.50 · Option exercise (M): 12,500 @ $22.40 · Option exercise (M): 6,250 @ $8.93 · Sale (S): 67,115 @ $36 · +5 more | EDGAR |
| 2025-02-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $16.23 · Sale (S): 10,000 @ $25 · Option exercise (M): 10,000 @ $17.44 · Sale (S): 10,000 @ $25 · Option exercise (M): 10,000 @ $17.96 · Sale (S): 10,000 @ $25 · +7 more | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 13,000 @ $0 · Sale (S): 3,348 @ $20.12 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 925 @ $18.94 | EDGAR |
| 2024-12-27 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 15,000 @ $12.67 · Sale (S): 15,000 @ $17.22 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 15,000 @ $12.67 · Sale (S): 12,090 @ $18.30 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 1,000 @ $0 · Sale (S): 2,820 @ $8.53 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 910 @ $9.07 | EDGAR |
| 2023-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 436 @ $16.59 · Sale (S): 122 @ $16.12 | EDGAR |
| 2023-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 10,000 @ $0 · Sale (S): 1,671 @ $21.75 · Sale (S): 360 @ $22.42 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 905 @ $21.90 · Sale (S): 192 @ $21.63 | EDGAR |
| 2022-09-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 349 @ $28 | EDGAR |
| 2022-05-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 436 @ $21.51 · Sale (S): 445 @ $21.92 | EDGAR |
| 2022-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 8,750 @ $0 · Sale (S): 798 @ $26.51 · Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 934 @ $24.58 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-01-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1882909 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs